PharmaEssentia Corporation Completes Secondary Offering of GDR Shares on Luxembourg Exchange
Taiwan-based PharmaEssentia Corporation (TPE: 6446) has announced the successful closing of a secondary offering of...
Lee’s Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its 2022 financial report, recording HKD...
Reistone Biopharma’s RSS0343 Receives NMPA Approval for Non-Cystic Fibrosis Bronchiectasis
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Pharmaceuticals (SHA: 600276) with an investment...
Siemens Healthineers and China Chest Pain Center Launch Smart Training Program
German healthcare giant Siemens Healthineers (ETR: SHL) has partnered with the China Chest Pain Center...
Neurodawn Pharmaceutical’s Y-1 Receives NMPA Approval for Primary Intracranial Tumor Treatment
Nanjing-based Neurodawn Pharmaceutical Co., Ltd has announced that its Category 1 drug, injectable Y-1, has...
Biosion Secures Series B+ Financing to Advance Antibody-Based Therapies Pipeline
Biosion, a global, clinical-stage biotech company dedicated to developing antibody-based therapies for immune and oncologic...
Jiangsu Hengrui Pharmaceuticals Reports 2022 Revenue Dip and Increased R&D Investment
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a China-based pharmaceutical company, has released its 2022 financial report,...
GenScript Biotech’s Subsidiary Legend Biotech Announces Positive CAR-T Therapy Results
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...
HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs
China-based HealZen Therapeutics has entered into a licensing agreement with compatriot firm NeuShen, focusing on...
AACR 2023 Highlights: CAR-T Therapies and Monoclonal Antibody Combinations in Cancer Research
The 2023 edition of the American Association for Cancer Research (AACR) annual meeting has concluded,...
Hasten Biopharmaceutical Secures $315 Million Investment for Pipeline Expansion
China-based Hasten Biopharmaceutical Co., Ltd has reportedly received USD 315 million in a fundraising round...
Staidson Pharmaceutical Plans RMB 580 Million Private Placement for Drug R&D
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced plans to raise RMB 580...
Sangon Biotech Secures RMB 2 Billion in First Financing Round to Boost Life Science Services
China-based contract research organization (CRO) Sangon Biotech has secured RMB 2 billion (USD 290.3 million)...
Shenzhen 01 Life Science Secures RMB 100 Million in Series B1 Financing for Microecology Platform
Shenzhen 01 Life Science and Technology Ltd. Co., Ltd, a company specializing in human big...
Pfizer’s Prevenar 13 Receives Expanded Age Range Approval in China
U.S.-based pharmaceutical giant Pfizer (NYSE: PFE) has reported receiving an additional indication approval from the...
BeiGene’s Tislelizumab-Chemo Combo Excels in RATIONALE 305 Trial for Gastric Cancer
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced that the...
Zylox-Tonbridge Medical Teams Up with Hicicare Science for Guide Wire Product Sales in China
China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced...
Shanghai Ark Biopharmaceutical’s STAR Market IPO Filing Accepted, Aims to Raise $289.6 Million
Shanghai Ark Biopharmaceutical Co., Ltd’s Initial Public Offering (IPO) filing to the Shanghai Stock Exchange’s...
Hunan Warrant Pharmaceutical Receives NMPA Approval for Generic Brivudine
Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving marketing...
Junshi Biosciences’ Tuoyi Combo Shows Promise in Phase III Neotorch Study for NSCLC
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has published the results of the Phase III...